These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 19201905

  • 21. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ.
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [Abstract] [Full Text] [Related]

  • 22. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
    Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K.
    J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
    [Abstract] [Full Text] [Related]

  • 23. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, Takashima M, Ueno T, Hinoda Y, Oka M.
    Anticancer Res; 2008 Mar; 28(1B):379-87. PubMed ID: 18383873
    [Abstract] [Full Text] [Related]

  • 24. Exogenous interleukin 2 regulates interleukin 6 and nitric oxide but not interferon gamma and tumor necrosis factor alpha production in bronchoalveolar leukocytes from patients with small cell lung cancer.
    Cembrzyńska-Nowak M, Bieńkowska M, Szklarz E.
    Arch Immunol Ther Exp (Warsz); 1998 Mar; 46(6):367-74. PubMed ID: 9883316
    [Abstract] [Full Text] [Related]

  • 25. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
    Imataki O, Heike Y, Makiyama H, Iizuka A, Ikarashi Y, Ishida T, Wakasugi H, Takaue Y.
    Cytotherapy; 2008 Mar; 10(5):497-506. PubMed ID: 18608348
    [Abstract] [Full Text] [Related]

  • 26. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S, Kreuzfelder E, Waydhas C, Schade FU, Flohé S.
    Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
    [Abstract] [Full Text] [Related]

  • 27. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I, Yamaguchi Y, Ohara M, Ikeda T, Okada M.
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [Abstract] [Full Text] [Related]

  • 28. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R.
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [Abstract] [Full Text] [Related]

  • 29. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
    Toh U, Fujii T, Tayama K, Yanaga H, Yokoyama G, Yamaguchi M, Horiuchi H, Sasatomi T, Takamori S, Shirouzu K, Seki N, Yamana H.
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
    [Abstract] [Full Text] [Related]

  • 30. Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study.
    Chan B, Lee W, Hu CX, Ng P, Li KW, Lo G, Ho G, Yeung DW, Woo D.
    Cytotherapy; 2003 Oct; 5(1):46-54. PubMed ID: 12745587
    [Abstract] [Full Text] [Related]

  • 31. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.
    Toyoda T, Kamata T, Tanaka K, Ihara F, Takami M, Suzuki H, Nakajima T, Ikeuchi T, Kawasaki Y, Hanaoka H, Nakayama T, Yoshino I, Motohashi S.
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188702
    [Abstract] [Full Text] [Related]

  • 32. Polarization of natural killer T cells towards an NKT2 subpopulation occurs after stimulation with alpha-galactosylceramide and rhG-CSF in aplastic anemia.
    Wang Y, Hu X, Guo C, Zhang Q, Peng J, Zhang J, Li L, Zhang T, Xu C.
    Acta Haematol; 2008 Mar; 119(3):178-86. PubMed ID: 18535366
    [Abstract] [Full Text] [Related]

  • 33. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
    Meehan KR, Wu J, Bengtson E, Hill J, Ely P, Szczepiorkowski Z, Kendall M, Ernstoff MS.
    Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
    [Abstract] [Full Text] [Related]

  • 34. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response.
    Eksioglu EA, Mahmood SS, Chang M, Reddy V.
    Exp Hematol; 2007 Aug; 35(8):1163-71. PubMed ID: 17562355
    [Abstract] [Full Text] [Related]

  • 35. Discrepancies of NKT cells expression in peripheral blood and in cerebrospinal fluid from Behçet's disease.
    Hamzaoui K, Kamoun M, Houman H, Hentati F, Hamza M, Ayed K, Hamzaoui A.
    J Neuroimmunol; 2006 Jun; 175(1-2):160-8. PubMed ID: 16624421
    [Abstract] [Full Text] [Related]

  • 36. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [Abstract] [Full Text] [Related]

  • 37. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
    Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R.
    Clin Cancer Res; 2005 Jun 01; 11(11):4160-7. PubMed ID: 15930352
    [Abstract] [Full Text] [Related]

  • 38. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, Lin HY, Soong SJ.
    J Immunother; 2009 Jun 01; 32(6):632-7. PubMed ID: 19483646
    [Abstract] [Full Text] [Related]

  • 39. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T, Tretter C, Gibson JJ, Cole BF, Schned AR, Harris R, Wallen EM, Fisher JL, Waugh MG, Truman D, Stempkowski LM, Crosby NA, Heaney J, Ernstoff MS.
    J Urol; 2004 Mar 01; 171(3):1036-42. PubMed ID: 14767265
    [Abstract] [Full Text] [Related]

  • 40. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun 01; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.